Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 56pembrolizumab 50Cisplatin 43Magnetic Resonance Spectroscopy 27enfortumab vedotin 22Specimen Handling 22Nivolumab 22Cystectomy 18durvalumab 16Carboplatin 16avelumab 15Mitomycin 14atezolizumab 13Docetaxel 13Cystoscopy 12Fluorouracil 11Radiation 9Transurethral Resection of Bladder 8Radiotherapy 8Ipilimumab 8sacituzumab govitecan 7Standard of Care 7Radiosurgery 7Paclitaxel 7Immunoglobulin G 7Disulfides 7erdafitinib 6cemiplimab 6Surveys and Questionnaires 6Surgical Procedures, Operative 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Panvac-VF × 1 year × Clear all
NCT02015104 2025-07-01

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
32 enrolled 16 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡